Literature DB >> 22130449

Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells.

E J Cheadle1, D G Rothwell, J S Bridgeman, V E Sheard, R E Hawkins, D E Gilham.   

Abstract

T cells bearing chimeric antigen receptors (CARs) are broadly categorised into first- and second-generation receptors. Second-generation CARs contain a co-stimulatory signalling molecule and have been shown to secrete IL-2, undergo greater proliferation and to have enhanced persistence in vivo. However, we have shown that T cells bearing a first-generation CAR containing a CD19-targeting scFv (single-chain variable fragment) and the CD3ζ-signalling domain are able to produce IL-2 upon co-culture with CD19(+) B-cell lymphomas independent of CD28 activity. Here, we report that signalling through endogenous CD2 following ligation with its ligands, CD48 in mouse and CD58 in humans, drives IL-2 production by first-generation CD19-specific CAR. Moreover, the high levels of IL-2 produced by human T cells engrafted with a second-generation CD28-containing CAR during target-cell recognition are dependent to a degree upon CD2 receptor activity. These observations highlight the fact that the functional activity induced by T-cell-expressed CARs is dependent upon endogenous 'natural' receptor interactions. A deeper understanding of the role of these activities will serve to further refine the design of future CARs to either exploit or avoid these interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130449     DOI: 10.1038/gt.2011.192

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

Review 1.  Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.

Authors:  Saad S Kenderian; David L Porter; Saar Gill
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-13       Impact factor: 5.742

Review 2.  Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?

Authors:  Yeison Santamaria-Alza; Gloria Vasquez
Journal:  Inflamm Res       Date:  2021-05-20       Impact factor: 4.575

Review 3.  Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.

Authors:  Marco Ruella; Carl H June
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 4.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 5.  Strategies to Address Chimeric Antigen Receptor Tonic Signaling.

Authors:  Adam Ajina; John Maher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.261

6.  CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.

Authors:  J S Bridgeman; K Ladell; V E Sheard; K Miners; R E Hawkins; D A Price; D E Gilham
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 7.  CAR T cells for brain tumors: Lessons learned and road ahead.

Authors:  David Akhavan; Darya Alizadeh; Dongrui Wang; Michael R Weist; Jennifer K Shepphird; Christine E Brown
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

Review 8.  CD2 Immunobiology.

Authors:  Christian Binder; Filip Cvetkovski; Felix Sellberg; Stefan Berg; Horacio Paternina Visbal; David H Sachs; Erik Berglund; David Berglund
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

Review 9.  Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.

Authors:  Muhammad Sadeqi Nezhad; Meghdad Abdollahpour-Alitappeh; Behzad Rezaei; Mahboubeh Yazdanifar; Alexander Marcus Seifalian
Journal:  Pharm Res       Date:  2021-06-10       Impact factor: 4.200

Review 10.  Clinical application of adoptive T cell therapy in solid tumors.

Authors:  Yi-Wen Zang; Xiao-Dong Gu; Jian-Bin Xiang; Zong-You Chen
Journal:  Med Sci Monit       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.